220 related articles for article (PubMed ID: 24037527)
1. The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies.
Shain KH; Tao J
Oncogene; 2014 Aug; 33(32):4107-13. PubMed ID: 24037527
[TBL] [Abstract][Full Text] [Related]
2. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
[TBL] [Abstract][Full Text] [Related]
4. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
[TBL] [Abstract][Full Text] [Related]
5. VLA-4 Expression and Activation in B Cell Malignancies: Functional and Clinical Aspects.
Härzschel A; Zucchetto A; Gattei V; Hartmann TN
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32210016
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance.
Mraz M; Zent CS; Church AK; Jelinek DF; Wu X; Pospisilova S; Ansell SM; Novak AJ; Kay NE; Witzig TE; Nowakowski GS
Br J Haematol; 2011 Oct; 155(1):53-64. PubMed ID: 21749361
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
[TBL] [Abstract][Full Text] [Related]
8. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting.
Kurtova AV; Tamayo AT; Ford RJ; Burger JA
Blood; 2009 May; 113(19):4604-13. PubMed ID: 19228923
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.
Bernard S; Danglade D; Gardano L; Laguillier C; Lazarian G; Roger C; Thieblemont C; Marzec J; Gribben J; Cymbalista F; Varin-Blank N; Ledoux D; Baran-Marszak F
Int J Cancer; 2015 Jun; 136(12):2761-74. PubMed ID: 25388373
[TBL] [Abstract][Full Text] [Related]
10. Targeting B cell receptor signalling in cancer: preclinical and clinical advances.
Burger JA; Wiestner A
Nat Rev Cancer; 2018 Mar; 18(3):148-167. PubMed ID: 29348577
[TBL] [Abstract][Full Text] [Related]
11. B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Koehrer S; Burger JA
Clin Adv Hematol Oncol; 2016 Jan; 14(1):55-65. PubMed ID: 27057669
[TBL] [Abstract][Full Text] [Related]
12. CD95 Signaling Inhibits B Cell Receptor-Mediated Gammaherpesvirus Replication in Apoptosis-Resistant B Lymphoma Cells.
Tan L; Zhang C; Dematos J; Kuang L; Jung JU; Liang X
J Virol; 2016 Nov; 90(21):9782-9796. PubMed ID: 27558422
[TBL] [Abstract][Full Text] [Related]
13. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
de Rooij MF; Kuil A; Geest CR; Eldering E; Chang BY; Buggy JJ; Pals ST; Spaargaren M
Blood; 2012 Mar; 119(11):2590-4. PubMed ID: 22279054
[TBL] [Abstract][Full Text] [Related]
14. CD40L mediated alternative NFκB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma.
Rauert-Wunderlich H; Rudelius M; Berberich I; Rosenwald A
Cell Death Dis; 2018 Jan; 9(2):86. PubMed ID: 29367645
[TBL] [Abstract][Full Text] [Related]
15. Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens.
Young RM; Wu T; Schmitz R; Dawood M; Xiao W; Phelan JD; Xu W; Menard L; Meffre E; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Staudt LM
Proc Natl Acad Sci U S A; 2015 Nov; 112(44):13447-54. PubMed ID: 26483459
[TBL] [Abstract][Full Text] [Related]
16. The B-cell receptor in control of tumor B-cell fitness: Biology and clinical relevance.
Casola S; Perucho L; Tripodo C; Sindaco P; Ponzoni M; Facchetti F
Immunol Rev; 2019 Mar; 288(1):198-213. PubMed ID: 30874349
[TBL] [Abstract][Full Text] [Related]
17. Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.
Saba NS; Liu D; Herman SE; Underbayev C; Tian X; Behrend D; Weniger MA; Skarzynski M; Gyamfi J; Fontan L; Melnick A; Grant C; Roschewski M; Navarro A; Beà S; Pittaluga S; Dunleavy K; Wilson WH; Wiestner A
Blood; 2016 Jul; 128(1):82-92. PubMed ID: 27127301
[TBL] [Abstract][Full Text] [Related]
18. B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies.
Puri KD; Di Paolo JA; Gold MR
Int Rev Immunol; 2013 Aug; 32(4):397-427. PubMed ID: 23886342
[TBL] [Abstract][Full Text] [Related]
19. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
Seda V; Mraz M
Eur J Haematol; 2015 Mar; 94(3):193-205. PubMed ID: 25080849
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways.
Medina DJ; Goodell L; Glod J; Gélinas C; Rabson AB; Strair RK
Haematologica; 2012 Aug; 97(8):1255-63. PubMed ID: 22371181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]